The results showed that the proportion of CD29+/CD90+ patients in pancreatic cancer tissues was substantially greater than in the responder group, and the rate of CD29+CD90+ in GC specimens was favorably connected with the clinical stage (Figures 2B, C). The gene discussed is THY1; the disease is familial pancreatic carcinoma.